利尿性肾图对小儿上尿路扩张的诊断意义

对３３例４４侧上尿路扩张的患儿进行利尿性肾图的检测，其时间活性曲线分成四种类型：Ⅰ型，无梗阻；Ⅱｂ、Ⅲ、Ⅳ型，有明显梗阻存在，其中２１侧接受手术，术中均发现有不同程度的上尿路梗阻性病变；Ⅱａ型，需定期随访，观察病情变化。利尿性肾图对鉴别小儿尿路梗阻是一较为简便、可靠的方法。     

POP-01脉冲电磁场型骨质疏松治疗系统的应用

目的评估脉冲电磁场型骨质疏松治疗系统作为一种骨质疏松非药物治疗方法的疗效。方法42例骨质疏松症患者。治疗组32例采用POP-01脉冲电磁场型骨质疏松治疗系统进行治疗(1次/d,45 min/次,30 d一个疗程),同时口服葡萄糖酸钙片(1 g,3次/d)。对照组10例同样口服葡萄糖酸钙片,共服30 d。试验前后均测量骨密度值(BMD,L2-L4的平均值),根据骨代谢化验值及疼痛症状的分级来评价症状的改善程度。结果治疗后治疗组BMD明显提高,平均增长率为9.8％,治疗前后BMD存在显著差异(P<0.001);BMD提高的有效率为87.5％,疼痛减轻的有效率为93.8％,治疗前后疼痛改善有显著差异(P<0.001);对照组BMD无明显变化,治疗前后BMD及疼痛改善均无显著差异。结论POP-01脉冲电磁场型骨质疏松治疗仪对提高骨质疏松患者的骨密度和改善其疼痛症状具有重要的价值。     

全反式维甲酸对乳腺癌MCF-7细胞增殖的影响

目的研究全反式维甲酸(ATRA)对乳腺癌MCF-7细胞增殖的影响.方法采用MTT法观察和比较MCF-7细胞在ATRA不同浓度和作用时间下的增殖能力.结果ATRA作用浓度为1 μmol/L时,第3、6、9 d的光吸收值均与对照组有显著差异(P<0.01),其中又以第6 d时ATRA对MCF-7细胞增殖的抑制作用最明显.结论ATRA对乳腺癌MCF-7细胞具有增殖抑制作用,且这种作用具有剂量和时间依赖性.     

蛛网膜松解剥离,大网膜移植治疗脑缺氧后遗症

目的:探索瘃缺氧后遗症的外科治疗。方法:用显微外科技术松解并部分切除增厚蛛网膜,再作单侧或双侧带蒂大网膜脑移植术。结果:全部病例术后经2年以上随访,显示运动,语言和智力有不同程度进步。结论:蛛网膜松解剥离大网膜移植可增进脑血液循不以及可能的神经介质的作用,使脑功能得以改善。     

Analysis on the factors affecting the efficacy of 131Ⅰ remnant ablation in patients after thyroidectomy for differentiated thyroid carcinoma

Objective 131Ⅰ is the most effective treatment for thyroidal remnant ablation after thy-roidectomy in patients with differentiated thyroid carcinoma (DTC). Ways to improve its therapeutic efficacy have been a major clinical concern. This study was designed to assess the efficacy of thyroid ablation by finding out its leading factors. Methods Eighty cases of post-operative DTC patients who had undergone first 131Ⅰ remnant ablation therapy were retrospectively reviewed. The efficacy of the therapy was assessed by a diagnostic 131Ⅰ whole body follow-up scan 3- 6 months later. The ablation therapy was considered to be suc-cessful only if no conceivable radioactivity was detected in the thyroidectomy bed. The χ2 test and multi-vari-ance Binary Logistic regression were used to analyze 9 variances which might affect the therapeutic efficacy, including gender, age (<45 years and ≥45 years), type of pathology (papillary or follicular carcinoma), metastasis, residual thyroid weight (low, median, high), 24 h radioiodine uptake ratio (< 10%, 10%-20%, >20%), thyroglobulin (Tg, negative or positive), thyroid stimulating hormone (TSH, <30 mU/L, 30-60 mU/L, >60 mU/L), and radioiodine dose (<1850 MBq,1850-3700 MBq, >3700 MBq). Results 131Ⅰ remnant ablation therapy was successful in 58 of 80 DTC patients (72.5%). Three variances were found to have affected the therapeutic efficacy: residual thyroid weight, 24 h radioiodine uptake ratio and 131Ⅰ dose. The corresponding intra-groups statistical difference of those 3 variances was significant by χ2 test (χ2 = 8.892, 9.528, 15.085, P = 0.012, 0.009, 0. 001), while the intra-group statistical differences of the remaining variances were insignificant (χ2 =0.486, 0. 051, 0. 322, 0. 010, 0. 006, 2. 575, all P > 0. 05). All 9 variances were analyzed by the multi-variance Binary Logistic regression model through for-ward stepwise. The variance of residual thyroid weight (X1) and 131Ⅰ dose (X2) were finally selected as the 2 key parameters in the formula, P=e(-0.865-0.868X1+1.677X2)/[1-e(-0.865-0.868X1+1.677X2)] , by the Binary Logistic regression analysis (Wald values were 3.752 and9. 130, P=0.049, 0.003). Conclusions The efficacy of 131Ⅰ ablation of thyroidal remnant in post-operative DTC patients was mainly determined by the re-sidual thyroid weight and the therapeutic 131Ⅰ dose. The other 7 factors included in this study were not found to be statistically significant.     

核医学在泌尿生殖系统中的应用

泌尿生殖系统的核医学检查包括肾动态显像测定肾功能、肾静态显像检查肾占位性病变、膀胱尿道反流显像、睾丸显像以及体外放射免疫分析(RIA)测定肾功能5部分。泌尿生殖系统的核医学检查方法简单、安全、可靠,可短期内重复检查和动态观察肾功能的变化,因此已被广泛用于协助诊断和评估疗效。该技术除在成人中普遍应用外,目前在儿科中用于肾盂积水的诊断和分肾(即左右肾)功能的测定也颇受临床医师的关注[1]。肾动态显像肾动态显像从20世纪60年代起用于临床,其能提供分肾功能和肾解剖两方面既独立又联系的信息。肾动态显像所获肾功能信息较特…     

Analysis on the factors affecting the efficacy of 131Ⅰ remnant ablation in patients after thyroidectomy for differentiated thyroid carcinoma

Objective 131Ⅰ is the most effective treatment for thyroidal remnant ablation after thy-roidectomy in patients with differentiated thyroid carcinoma (DTC). Ways to improve its therapeutic efficacy have been a major clinical concern. This study was designed to assess the efficacy of thyroid ablation by finding out its leading factors. Methods Eighty cases of post-operative DTC patients who had undergone first 131Ⅰ remnant ablation therapy were retrospectively reviewed. The efficacy of the therapy was assessed by a diagnostic 131Ⅰ whole body follow-up scan 3- 6 months later. The ablation therapy was considered to be suc-cessful only if no conceivable radioactivity was detected in the thyroidectomy bed. The χ2 test and multi-vari-ance Binary Logistic regression were used to analyze 9 variances which might affect the therapeutic efficacy, including gender, age (<45 years and ≥45 years), type of pathology (papillary or follicular carcinoma), metastasis, residual thyroid weight (low, median, high), 24 h radioiodine uptake ratio (< 10%, 10%-20%, >20%), thyroglobulin (Tg, negative or positive), thyroid stimulating hormone (TSH, <30 mU/L, 30-60 mU/L, >60 mU/L), and radioiodine dose (<1850 MBq,1850-3700 MBq, >3700 MBq). Results 131Ⅰ remnant ablation therapy was successful in 58 of 80 DTC patients (72.5%). Three variances were found to have affected the therapeutic efficacy: residual thyroid weight, 24 h radioiodine uptake ratio and 131Ⅰ dose. The corresponding intra-groups statistical difference of those 3 variances was significant by χ2 test (χ2 = 8.892, 9.528, 15.085, P = 0.012, 0.009, 0. 001), while the intra-group statistical differences of the remaining variances were insignificant (χ2 =0.486, 0. 051, 0. 322, 0. 010, 0. 006, 2. 575, all P > 0. 05). All 9 variances were analyzed by the multi-variance Binary Logistic regression model through for-ward stepwise. The variance of residual thyroid weight (X1) and 131Ⅰ dose (X2) were finally selected as the 2 key parameters in the formula, P=e(-0.865-0.868X1+1.677X2)/[1-e(-0.865-0.868X1+1.677X2)] , by the Binary Logistic regression analysis (Wald values were 3.752 and9. 130, P=0.049, 0.003). Conclusions The efficacy of 131Ⅰ ablation of thyroidal remnant in post-operative DTC patients was mainly determined by the re-sidual thyroid weight and the therapeutic 131Ⅰ dose. The other 7 factors included in this study were not found to be statistically significant.     

全反式维甲酸对乳腺癌MCF-7细胞增殖的影响

目的研究全反式维甲酸(ATRA)对乳腺癌MCF-7细胞增殖的影响。方法采用MTT法观察和比较MCF-7细胞在ATRA不同浓度和作用时间下的增殖能力。结果ATRA作用浓度为1μmol/L时,第3、6、9d的光吸收值均与对照组有显著差异(P<0.01),其中又以第6d时ATRA对MCF-7细胞增殖的抑制作用最明显。结论ATRA对乳腺癌MCF-7细胞具有增殖抑制作用,且这种作用具有剂量和时间依赖性。     

儿童恶性肿瘤股骨转移的骨显像和MRI比较

目的比较骨显像和MRI在儿童恶性肿瘤股骨转移中的应用价值.方法对经病理检查确诊的25例恶性肿瘤患儿（神经母细胞瘤12例,淋巴瘤8例,原始神经外胚层肿瘤2例,横纹肌肉瘤3例）分别行全身骨显像和双侧股骨MRI,MRI采用自旋回波T1WI及短时反转恢复（STIR）序列冠状面成像.结果12例神经母细胞瘤患儿中骨显像阳性7例,可疑2例,阴性3例,7例阳性、2例可疑及1例阴性病例MRI检查均阳性;8例淋巴瘤骨显像阳性5例,阴性3例,5例阳性及2例阴性患儿MRI阳性;2例原始神经外胚层肿瘤骨显像与MRI均阳性;3例横纹肌肉瘤骨显像阳性2例,阴性1例,MRI均阳性.此外,MRI发现股骨的异常信号范围大于骨显像.结论在儿童恶性肿瘤骨转移中联合应用骨显像和MRI有助于尽早诊断及提高诊断准确性.     

Analysis on the factors affecting the efficacy of 131Ⅰ remnant ablation in patients after thyroidectomy for differentiated thyroid carcinoma

Objective 131Ⅰ is the most effective treatment for thyroidal remnant ablation after thy-roidectomy in patients with differentiated thyroid carcinoma (DTC). Ways to improve its therapeutic efficacy have been a major clinical concern. This study was designed to assess the efficacy of thyroid ablation by finding out its leading factors. Methods Eighty cases of post-operative DTC patients who had undergone first 131Ⅰ remnant ablation therapy were retrospectively reviewed. The efficacy of the therapy was assessed by a diagnostic 131Ⅰ whole body follow-up scan 3- 6 months later. The ablation therapy was considered to be suc-cessful only if no conceivable radioactivity was detected in the thyroidectomy bed. The χ2 test and multi-vari-ance Binary Logistic regression were used to analyze 9 variances which might affect the therapeutic efficacy, including gender, age (<45 years and ≥45 years), type of pathology (papillary or follicular carcinoma), metastasis, residual thyroid weight (low, median, high), 24 h radioiodine uptake ratio (< 10%, 10%-20%, >20%), thyroglobulin (Tg, negative or positive), thyroid stimulating hormone (TSH, <30 mU/L, 30-60 mU/L, >60 mU/L), and radioiodine dose (<1850 MBq,1850-3700 MBq, >3700 MBq). Results 131Ⅰ remnant ablation therapy was successful in 58 of 80 DTC patients (72.5%). Three variances were found to have affected the therapeutic efficacy: residual thyroid weight, 24 h radioiodine uptake ratio and 131Ⅰ dose. The corresponding intra-groups statistical difference of those 3 variances was significant by χ2 test (χ2 = 8.892, 9.528, 15.085, P = 0.012, 0.009, 0. 001), while the intra-group statistical differences of the remaining variances were insignificant (χ2 =0.486, 0. 051, 0. 322, 0. 010, 0. 006, 2. 575, all P > 0. 05). All 9 variances were analyzed by the multi-variance Binary Logistic regression model through for-ward stepwise. The variance of residual thyroid weight (X1) and 131Ⅰ dose (X2) were finally selected as the 2 key parameters in the formula, P=e(-0.865-0.868X1+1.677X2)/[1-e(-0.865-0.868X1+1.677X2)] , by the Binary Logistic regression analysis (Wald values were 3.752 and9. 130, P=0.049, 0.003). Conclusions The efficacy of 131Ⅰ ablation of thyroidal remnant in post-operative DTC patients was mainly determined by the re-sidual thyroid weight and the therapeutic 131Ⅰ dose. The other 7 factors included in this study were not found to be statistically significant.